Organigram Global (NASDAQ:OGI) Posts Earnings Results, Misses Expectations By $0.04 EPS

Posted by Geri Gentry on Aug 11th, 2026

Organigram Global (NASDAQ:OGI – Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.04), Zacks reports. Organigram Global had a negative return on equity of 13.41% and a negative net margin of 9.22%.

Here are the key takeaways from Organigram Global’s conference call:

Record financial performance: Q3 net revenue rose 49% year over year to CAD 105.8 million, while adjusted EBITDA reached a record CAD 13.4 million and adjusted gross margin expanded to 37%. Management expects fiscal 2026 revenue to exceed CAD 350 million, with margins and EBITDA meaningfully above fiscal 2025 levels.
Sanity Group is scaling as planned: The German business contributed €24.5 million of revenue during OrganiGram’s ownership period, and international sales represented roughly 35% of consolidated revenue. Management expects Sanity’s revenue growth to continue, with operating expenses remaining relatively stable and creating further P&L leverage.
Canadian product recovery is gaining traction: New vape hardware and higher-potency products helped improve vape share in June, while infused pre-rolls returned to growth. Flower share increased to 12.5% year over year, and beverages and concentrates also posted strong gains as the company reduces its SKU count and focuses on higher-performing products.
International supply and margin opportunities remain significant: OrganiGram is improving Canadian flower pass rates, adding suppliers, and pursuing EU GMP-compliant remediation pathways to meet tight German demand. EU GMP certification could meaningfully improve margins by reducing reliance on European processing, although no approval timeline was provided.
Cash flow remains a near-term concern: Free cash flow was negative CAD 3.9 million in Q3, and management expects negative free cash flow for fiscal 2026 because of working-capital investments supporting the larger Sanity-led business. Cash and cash equivalents were CAD 11.7 million at quarter end, although total liquidity including debt facilities was CAD 49.2 million.

Organigram Global Stock Up 11.5%

OGI traded up $0.12 during trading on Tuesday, hitting $1.17. The company’s stock had a trading volume of 18,019,922 shares, compared to its average volume of 751,448. Organigram Global has a twelve month low of $0.85 and a twelve month high of $2.24. The stock’s fifty day moving average price is $0.98 and its 200-day moving average price is $1.24. The firm has a market capitalization of $165.09 million, a P/E ratio of -8.96 and a beta of 1.46.

Institutional Investors Weigh In On Organigram Global

Several hedge funds and other institutional investors have recently bought and sold shares of OGI. Millennium Management LLC bought a new position in shares of Organigram Global in the 4th quarter worth $1,260,000. Renaissance Technologies LLC lifted its stake in shares of Organigram Global by 43.2% in the fourth quarter. Renaissance Technologies LLC now owns 1,405,348 shares of the company’s stock valued at $2,361,000 after buying an additional 423,900 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Organigram Global by 16.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 193,547 shares of the company’s stock valued at $325,000 after buying an additional 26,733 shares during the last quarter. Goldman Sachs Group Inc. increased its position in shares of Organigram Global by 82.1% during the fourth quarter. Goldman Sachs Group Inc. now owns 466,585 shares of the company’s stock worth $784,000 after acquiring an additional 210,391 shares in the last quarter. Finally, Two Sigma Investments LP acquired a new stake in shares of Organigram Global in the 3rd quarter worth about $907,000. 34.63% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on OGI shares. Wall Street Zen lowered shares of Organigram Global from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Organigram Global in a research note on Tuesday, June 9th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Organigram Global has an average rating of “Hold”.

Read Our Latest Stock Report on Organigram Global

About Organigram Global

(Get Free Report)

Organigram Global Inc (NASDAQ: OGI) is a licensed producer of cannabis and hemp products headquartered in Moncton, New Brunswick, Canada. Founded in 2013, the company operates a state-of-the-art cultivation and manufacturing facility spanning more than one million square feet. Organigram holds licenses from Health Canada to produce and sell both medical and adult-use cannabis, and it pursues Good Manufacturing Practice (GMP) certification to support international exports.

The company’s product portfolio encompasses dried flower, pre-rolled joints, cannabis oils, capsules and soft gels, as well as vapourizer cartridges and extracts.